Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barnaby Nelson

Showing results (221-230 of 311) with videos related to

Pageof 32
Sort By:
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|July 6, 2023
Differential Expression of Anomalous Self-Experiences in Spontaneous Speech in Clinical High-Risk and Early-Course Psychosis Quantified by Natural Language ProcessingAgrima Srivastava, Alexandria Selloni, Zarina R Bilgrami, et al.
Early Intervention in Psychiatry|October 5, 2022
Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study)Brian O'Donoghue, Kelly Allott, Susy Harrigan, et al.
Early Intervention in Psychiatry|January 7, 2026
Feasibility of a Stepped-Care Intervention for Those at Clinical High Risk for Psychosis in the United StatesDaniel I Shapiro, Rebecca E Grattan, Jill R Laquidara, et al.
NPP - Digital Psychiatry and Neuroscience|March 24, 2025
"Ask" or "Inquire": operationalizing speech formality in psychosis and its risk states using etymologyMatthew Cotter, Alessia McGowan, Zarina Bilgrami, et al.
Frontiers in Psychiatry|August 9, 2022
Differential trajectories of tobacco smoking in people at ultra-high risk for psychosis: Associations with clinical outcomesFrederike Schirmbeck, Els van der Ven, Lindy-Lou Boyette, et al.
Translational Psychiatry|June 10, 2023
Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trialKelly Allott, Hok Pan Yuen, Lara Baldwin, et al.
The Australian and New Zealand Journal of Psychiatry|August 26, 2025
Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO studyMonika Schlögelhofer, Ashleigh Lin, Connie Markulev, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|November 26, 2025
Exploring the interconnections between baseline symptoms in ultra-high risk youth who did and did not transition to psychosis over three years: A network analysis comparisonGabriele Lo Buglio, Simon Hartmann, Tommaso Boldrini, et al.
Schizophrenia Research. Cognition|March 14, 2022
Digital technology for addressing cognitive impairment in recent-onset psychosis: A perspectiveImogen Bell, Roos M C A Pot-Kolder, Stephen J Wood, et al.
Schizophrenia (Heidelberg, Germany)|April 17, 2025
PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sampleStefania Tognin, Sandra Vieira, Dominic Oliver, et al.
Pageof 32

Showing results (221-230 of 311) with videos related to

Sort By:
Pageof 32
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|July 6, 2023
Differential Expression of Anomalous Self-Experiences in Spontaneous Speech in Clinical High-Risk and Early-Course Psychosis Quantified by Natural Language ProcessingAgrima Srivastava, Alexandria Selloni, Zarina R Bilgrami, et al.
Early Intervention in Psychiatry|October 5, 2022
Isolating the impact of antipsychotic medication on metabolic health: Secondary analysis of a randomized controlled trial of antipsychotic medication versus placebo in antipsychotic medication naïve first-episode psychosis (the STAGES study)Brian O'Donoghue, Kelly Allott, Susy Harrigan, et al.
Early Intervention in Psychiatry|January 7, 2026
Feasibility of a Stepped-Care Intervention for Those at Clinical High Risk for Psychosis in the United StatesDaniel I Shapiro, Rebecca E Grattan, Jill R Laquidara, et al.
NPP - Digital Psychiatry and Neuroscience|March 24, 2025
"Ask" or "Inquire": operationalizing speech formality in psychosis and its risk states using etymologyMatthew Cotter, Alessia McGowan, Zarina Bilgrami, et al.
Frontiers in Psychiatry|August 9, 2022
Differential trajectories of tobacco smoking in people at ultra-high risk for psychosis: Associations with clinical outcomesFrederike Schirmbeck, Els van der Ven, Lindy-Lou Boyette, et al.
Translational Psychiatry|June 10, 2023
Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trialKelly Allott, Hok Pan Yuen, Lara Baldwin, et al.
The Australian and New Zealand Journal of Psychiatry|August 26, 2025
Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO studyMonika Schlögelhofer, Ashleigh Lin, Connie Markulev, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|November 26, 2025
Exploring the interconnections between baseline symptoms in ultra-high risk youth who did and did not transition to psychosis over three years: A network analysis comparisonGabriele Lo Buglio, Simon Hartmann, Tommaso Boldrini, et al.
Schizophrenia Research. Cognition|March 14, 2022
Digital technology for addressing cognitive impairment in recent-onset psychosis: A perspectiveImogen Bell, Roos M C A Pot-Kolder, Stephen J Wood, et al.
Schizophrenia (Heidelberg, Germany)|April 17, 2025
PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sampleStefania Tognin, Sandra Vieira, Dominic Oliver, et al.
Pageof 32